Answers are grounded in this paper and cite their sources.
Cell-based models show pyrimethamine promotes apoptosis in mucoepidermoid carcinoma, suggesting new treatment options.
Background Mucoepidermoid carcinoma (MEC) is the most prevalent salivary gland malignancy, with a poor prognosis in high‐grade tumors at diagnosis. This highlights the need for effective antitumor agents for treating MEC. Therefore, we aimed to investigate the antineoplastic efficacy of pyrimethamine (PYR), a Food and Drug Administration‐approved antiparasitic medicine, to repurpose it as an alternative therapeutic option for treating human MEC. Methods The trypan blue exclusion assay, cell counting kit‐8 assay, and live/dead assay were performed to assess the antiproliferative efficacy of PYR. PYR‐induced apoptosis was confirmed with 4′,6‐diamidino‐2‐phenylindole staining, cell cycle analysis, and annexin V/propidium iodide staining. A western blot assay was conducted to measure changes in cleaved caspase 8 and myeloid cell leukemia‐1 (Mcl‐1) expression after PYR treatment. Mcl‐1 overexpression was used to further confirm the apoptosis‐inducing activity of PYR. The hanging drop method was employed to assess the efficacy of PYR in a three‐dimensional culture system. Results PYR‐induced apoptotic cell death in the YD‐15 high‐grade MEC cell line by promoting apoptosis, as evidenced by MCl‐1 proteasomal degradation and increased cleaved caspase 8 expression. Conclusion Our results indicate that PYR can effectively target human MEC by inducing both intrinsic and extrinsic apoptotic pathways.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: